HC Wainwright Reaffirms Neutral Rating for Co-Diagnostics (NASDAQ:CODX)

Co-Diagnostics (NASDAQ:CODX)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $1.50 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.21% from the stock’s previous close.

Co-Diagnostics Stock Down 0.8 %

Shares of CODX opened at $1.17 on Monday. Co-Diagnostics has a 52-week low of $1.00 and a 52-week high of $2.23. The company has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $1.26. The company has a market capitalization of $37.33 million, a PE ratio of -0.85 and a beta of -0.84.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. Koss Olinger Consulting LLC acquired a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned about 0.19% of Co-Diagnostics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.